Dipeptidyl peptidase-4 inhibitors (DPP4is) are another novel class of glucose-lowering drugs that are recommended as a second-line or add-on to metformin to reduce HbA1c in T2DM patients [7]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.